AUD24.95
0.28% day before yesterday
Australia, Dec 27, 06:10 am CET
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Telix Pharmaceuticals Stock price

AUD24.95
+1.59 6.81% 1M
+6.55 35.60% 6M
+14.87 147.52% YTD
+15.18 155.37% 1Y
+17.07 216.62% 3Y
+23.37 1,479.11% 5Y
+24.18 3,140.26% 10Y
Australia, Closing price Fri, Dec 27 2024
-0.07 0.28%
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Key metrics

Market capitalization AUD8.35b
Enterprise Value AUD8.25b
P/E (TTM) P/E ratio 165.45
EV/FCF (TTM) EV/FCF 241.58
EV/Sales (TTM) EV/Sales 12.78
P/S ratio (TTM) P/S ratio 12.93
P/B ratio (TTM) P/B ratio 20.64
Revenue growth (TTM) Revenue growth 80.92%
Revenue (TTM) Revenue AUD645.68m
EBIT (operating result TTM) EBIT AUD64.84m
Free Cash Flow (TTM) Free Cash Flow AUD34.17m
Cash position AUD118.84m
EPS (TTM) EPS AUD0.15
P/E forward 170.62
P/S forward 10.83
EV/Sales forward 10.71
Show more

Is Telix Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Telix Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Telix Pharmaceuticals forecast:

6x Buy
75%
1x Hold
13%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Telix Pharmaceuticals forecast:

Buy
75%
Hold
13%
Sell
13%

Financial data from Telix Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
646 646
81% 81%
100%
- Direct Costs 182 182
18% 18%
28%
463 463
241% 241%
72%
- Selling and Administrative Expenses 209 209
368% 368%
32%
- Research and Development Expense 183 183
188% 188%
28%
72 72
161% 161%
11%
- Depreciation and Amortization 7.34 7.34
24% 24%
1%
EBIT (Operating Income) EBIT 65 65
198% 198%
10%
Net Profit 49 49
204% 204%
8%

In millions AUD.

Don't miss a Thing! We will send you all news about Telix Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Christian Behrenbruch
Founded 2017
Website www.telixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today